Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Classical hematology 1

Conditions

Venous Thrombosis 2Pulmonary Embolism 2Hemorrhage 2Venous Thromboembolism 1Thromboembolism 1Thrombocytopenia 1Pancreatic Neoplasms 1Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1

Interventions

Gemcitabine 3Ethanol 3fish oil triglycerides 2S 1 (combination) 2Metronidazole 2Long-Term Synaptic Depression 2Dexamethasone 2pembrolizumab 1pasireotide 1nimotuzumab 1ferumoxtran-10 1alanylglutamine 1Tobacco Use Cessation Devices 1TachoSil 1Sunitinib 1Psychiatric Rehabilitation 1Pregabalin 1Polymerase Chain Reaction 1Polygeline 1Parenteral Nutrition 1Pancrelipase 1Oxaliplatin 1Nutritional Status 1Needles 1Mirtazapine 1Midazolam 1Meperidine 1Immunonutrition Diet 1Hydrocortisone 1Glucocorticoids 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Pancreatic Neoplasms × Dalteparin × Clear all
NCT00966277 2016-12-12

Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients

M.D. Anderson Cancer Center

Phase 4 Completed
87 enrolled 9 charts
Classical hematologyGastrointestinal

Pancreatic Neoplasms, Pulmonary Embolism, Venous Thrombosis, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡